Citadel Advisors
RXRX icon

Citadel Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Citadel Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.1M Sell
1,009,800
-969,000
-49% -$3.74M ﹤0.01% 5198
2025
Q4 		$8.09M Buy
1,978,800
+35,700
+2% +$177K ﹤0.01% 3541
2025
Q3 		$9.48M Buy
1,943,100
+227,538
+13% +$1.19M ﹤0.01% 3361
2025
Q2 		$8.68M Buy
1,715,562
+1,343,775
+361% +$6.6M ﹤0.01% 3232
2025
Q1 		$1.97M Sell
371,787
-142,846
-28% -$1.04M ﹤0.01% 5566
2024
Q4 		$3.48M Buy
514,633
+215,333
+72% +$1.45M ﹤0.01% 4592
2024
Q3 		$1.97M Buy
299,300
+42,900
+17% +$308K ﹤0.01% 5563
2024
Q2 		$1.92M Buy
256,400
+35,200
+16% +$307K ﹤0.01% 5396
2024
Q1 		$2.21M Buy
221,200
+93,000
+73% +$1.04M ﹤0.01% 5336
2023
Q4 		$1.26M Buy
128,200
+49,500
+63% +$353K ﹤0.01% 6228
2023
Q3 		$602K Buy
78,700
+53,600
+214% +$535K ﹤0.01% 7659
2023
Q2 		$187K Buy
25,100
+2,900
+13% +$20.3K ﹤0.01% 9996
2023
Q1 		$148K Buy
22,200
+3,100
+16% +$24.6K ﹤0.01% 10660
2022
Q4 		$147K Buy
19,100
+100
+0.5% +$981 ﹤0.01% 10634
2022
Q3 		$202K Sell
19,000
-9,800
-34% -$99.3K ﹤0.01% 10383
2022
Q2 		$234K Buy
28,800
+7,700
+36% +$51.5K ﹤0.01% 10366
2022
Q1 		$151K Buy
21,100
+3,700
+21% +$39.3K ﹤0.01% 11853
2021
Q4 		$298K Sell
17,400
-20,400
-54% -$384K ﹤0.01% 10943
2021
Q3 		$870K Buy
37,800
+31,500
+500% +$893K ﹤0.01% 8499
2021
Q2 		$230K Buy
+6,300
New +$186K ﹤0.01% 11859

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors's RXRX Position: Q1 2026 in Review

Citadel Advisors reduced its Recursion Pharmaceuticals (RXRX) stake by 85% in Q1 2026, selling an estimated $13.9M and leaving 624,659 shares worth $1.92M. The position accounts for ﹤0.01% of the portfolio, ranked #6142.

Citadel Advisors first reported a position in RXRX in Q4 2021 and has held it in 18 quarters since. The position peaked at $18.5M in Q4 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Citadel Advisors held 624,659 shares of Recursion Pharmaceuticals worth $1.92M as of Q1 2026.
  • Citadel Advisors sold 3,605,340 Recursion Pharmaceuticals shares in Q1 2026, an estimated $13.9M.
  • Recursion Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6142 holding.
  • Citadel Advisors first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
  • Citadel Advisors's Recursion Pharmaceuticals position peaked at $18.5M in Q4 2024.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.